Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer

This research study is for people who were treated with tremelimumab and durvalumab for advanced liver cancer and who are currently receiving durvalumab. Participants in this study will receive a drug called zanzalintinib. They will also continue receiving durvalumab. Studies have shown that patients with advanced liver cancer who had tremelimumab and durvalumab may benefit from taking zanzalintinib while they are taking durvalumab. Zanzalintinib is an investigational drug. This means it has not been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with advanced liver cancer. Durvalumab is approved by the FDA for patients with advanced liver cancer. The purpose of this study is to find out if taking zanzalintinib with durvalumab will improve how long people with advanced liver cancer will live.

NCT Number	NCT07226063
Lead Sponsor	Amit Mahipal Collaborators: Exelixis
Conditions	Hepatocellular Carcinoma, Liver Cancer
Enrollment	16 participants
Start Date	2026-05
Primary Completion	2028-02 (estimated)
Study Completion	2028-08 (estimated)
Updated on ClinicalTrials.gov	2026-05-05